In detail, combination therapy was able to induce a strong antitumor immune response, characterized by increased tumor infiltration of CD4+ and CD8+ T-cells and a reduced frequency of MDSCs, resulting in increased tumor regression and prolonged survival in metastatic mice [68]. This evidence concerns the gene CD4 and neoplasm.